Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil REP recurrent flare retreatment trial in generalized pustular psoriasis
2022-502128-38-00Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 4, open-label, single-arm trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by LEO Pharma. Started Oct 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on 2022-502128-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502128-38-00.